What Is an MPN (Myeloproliferative Neoplasm)?

Myeloproliferative neoplasms, commonly called MPNs, are a group of blood cancers in which the bone marrow overproduces one or more types of blood cells. Unlike many cancers that form solid tumors, MPNs are driven by mutations in blood-forming stem cells that cause them to churn out too many red blood cells, white blood cells, or platelets. The word “neoplasm” means abnormal new growth, and “myeloproliferative” refers to the myeloid cell line in the marrow growing out of control. Despite being classified as cancers, many MPNs are chronic conditions that people live with for years or even decades, though each subtype carries distinct risks that make understanding them genuinely important.

The Main Types of MPN

The World Health Organization recognizes several subtypes under the MPN umbrella. The four broad categories are chronic myeloid leukemia (CML), the classical Philadelphia-negative MPNs, the non-classical Philadelphia-negative MPNs, and MPNs that don’t fit neatly into any box, labeled MPN-unclassifiable.¹ CML is set apart because it is driven by a specific chromosomal abnormality called the Philadelphia chromosome. The remaining “Philadelphia-negative” MPNs lack that abnormality and are the ones most people encounter when they hear the term MPN. The three classical Philadelphia-negative MPNs are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).²

Each subtype reflects which blood-cell line is most affected. Polycythemia vera involves overproduction of red blood cells, which thickens the blood. Essential thrombocythemia centers on excessive platelet production. Primary myelofibrosis is characterized by scarring (fibrosis) of the bone marrow, which disrupts normal blood-cell manufacturing and often leads to an enlarged spleen as the body tries to produce blood cells elsewhere.³ Although these three diseases look different on a blood test, they share a surprising amount of molecular machinery under the hood.

The Genetic Mutations That Drive MPNs

The discovery of the JAK2 V617F mutation in 2005 was a turning point for the entire field. This single mutation in the Janus kinase 2 gene acts like a stuck “on” switch, telling blood-forming stem cells to keep dividing even when the body doesn’t need more cells.⁴ Nearly all PV patients carry the JAK2 V617F mutation, and it’s also found in a large share of ET and PMF patients. Beyond JAK2, two other “driver” mutations play central roles: mutations in the calreticulin gene (CALR) and in the MPL gene. All three feed into the same signaling pathway that regulates blood cell growth.⁵

In primary myelofibrosis, the breakdown by mutation type is roughly as follows: about 58% of patients carry JAK2 mutations, around 25% carry CALR mutations, and about 8% carry MPL mutations. A smaller group, close to 9%, test negative for all three and are called “triple negative.”⁶ Which mutation you carry matters clinically. In essential thrombocythemia, for instance, patients with JAK2 mutations tend to be older and have a thrombosis risk roughly double that of CALR-mutated patients, while those with CALR mutations face almost no risk of their disease evolving into polycythemia vera.⁷ Researchers now view JAK2-mutated ET and polycythemia vera as essentially two faces of one disease, with CALR-mutated ET being biologically distinct.

How Common Are MPNs

MPNs are rare compared with common solid tumors, but they’re not as uncommon as people sometimes assume. Using U.S. population data, the overall incidence rates are roughly 1.6 per 100,000 people per year for both PV and ET, and about 0.4 per 100,000 for primary myelofibrosis.⁸ The incidence of ET has been rising, possibly because of improved detection and broader use of blood testing. Men are more commonly affected across most MPN subtypes, though ET is a notable exception where rates are roughly equal between sexes or even slightly favor women.⁹

Survival varies dramatically by subtype. Five-year mortality rates in U.S. data were about 19% for both ET and PV, but jumped to roughly 51% for primary myelofibrosis.¹⁰ Younger patients and women generally have better survival across all types. Singapore’s population-based data show a broadly similar pattern: five-year relative survival rates above 95% for PV and ET, dropping to around 53% for PMF.¹¹ These numbers underscore that ET and PV are relatively indolent for most patients, while myelofibrosis is a more aggressive condition that requires closer monitoring and more active treatment.

Symptoms and What They Feel Like Day-to-Day

Many people with ET or early PV have no symptoms at all and learn about their MPN only when a routine blood test shows abnormally high cell counts. When symptoms do appear, they can be surprisingly nonspecific: fatigue, headaches, dizziness, night sweats, itching, bone pain, difficulty concentrating (sometimes called “brain fog”), and a sensation of fullness in the abdomen from an enlarged spleen. People with higher symptom scores consistently report lower quality of life and greater emotional distress.¹²

One symptom worth highlighting is aquagenic pruritus, an intense itching triggered by contact with water, including warm baths or showers. It occurs frequently in polycythemia vera and has long baffled patients and physicians alike. Research points to an accumulation of mast cells in the skin as a key contributor: these cells, which normally play a role in allergic reactions, appear in far greater numbers in PV patients who itch, and the itching correlates with skin mast cell counts rather than blood histamine levels.¹³ Mouse studies have shown that JAK2 inhibitors can reduce mast cell numbers and relieve the itching, which partly explains why these drugs help PV patients feel better even beyond their effects on blood counts.¹⁴

Blood Clots and Bleeding

The most dangerous day-to-day risk for people with MPNs is abnormal clotting. The disease creates a sort of paradox: too many blood cells and overactive platelets tip the balance toward clots, yet the same abnormalities can also predispose to bleeding. In essential thrombocythemia, about 11% of patients experience arterial clots (like strokes or heart attacks), 7% develop venous clots (like deep vein thrombosis), and around 8% have significant bleeding events.¹⁵

The mechanism behind this is genuinely complex. Platelets circulate in a hyperactive state, expressing more surface molecules that promote clotting and adhesion. White blood cells cross-talk with platelets and the lining of blood vessels, amplifying inflammation and clot formation in a process sometimes called “thromboinflammation.” Even red blood cells in MPNs show abnormal stickiness to vessel walls.¹⁶ All of these elements interact: it isn’t just that the blood is thicker, it’s that multiple cell types are cooperating to create a pro-clotting environment throughout the circulatory system.¹⁷

One counterintuitive finding involves extreme platelet counts in ET. You might expect that the more platelets in the blood, the higher the bleeding risk, but a study comparing patients with extremely high platelet counts to those with moderate elevations found no statistically significant difference in major bleeding.¹⁸ The platelet count alone isn’t a reliable predictor of who will bleed, which is one reason doctors weigh multiple factors rather than treating a number in isolation.

How MPNs Are Diagnosed

Diagnosing an MPN usually starts with a simple observation: something looks off on a complete blood count. A persistently elevated hemoglobin might point toward PV, a sky-high platelet count toward ET, and unusual cell shapes or counts paired with anemia toward myelofibrosis. But blood counts alone can’t clinch the diagnosis. A bone marrow biopsy is considered crucial, particularly for the Philadelphia-negative MPNs, because the pattern of cell growth and the degree of fibrosis in the marrow help distinguish one subtype from another.¹⁹

Molecular testing has become equally important. The current WHO classification builds genetic markers into the diagnostic criteria for every MPN subtype. Finding a JAK2 V617F mutation in a patient with high hemoglobin strongly supports a PV diagnosis. In ET or PMF, testing expands to include CALR and MPL. If all three driver mutations are absent, the search widens to other clonal markers and the bone marrow biopsy takes on even more weight. This layered approach, combining blood counts, marrow morphology, and molecular testing, is what allows hematologists to sort patients into the correct subtype and plan treatment accordingly.

When MPNs Progress or Transform

One of the most anxiety-provoking aspects of living with an MPN is the possibility that the disease will progress. PV and ET can evolve into myelofibrosis over the years, and all three classical MPNs carry a risk of transforming into acute myeloid leukemia (AML), sometimes called blast-phase MPN.²⁰ The leukemia that arises from an MPN is notoriously difficult to treat, with outcomes that are considerably worse than de novo AML.

What flips the switch from chronic MPN to leukemia is an area of active research. Genomic profiling of post-MPN leukemia samples has revealed that mutations in the TP53 gene are common in patients whose disease transforms. In the chronic phase of MPN, TP53 mutations are rarely found, but they appear to be selected for and drive clonal dominance during leukemic transformation.²¹ Beyond TP53, so-called “non-driver” mutations in splicing and epigenetic genes also raise alarms. Patients who carry mutations in SRSF2, U2AF1, or IDH1/2 at the time of their MPN diagnosis have a markedly higher risk of blast transformation compared to those without these mutations.²² In myelofibrosis specifically, epigenetic mutations tend to cluster with spliceosome mutations, forming a pattern of “clonal complexity” that signals more aggressive disease.²³

Treatment Options

Treatment for MPNs is tailored to the subtype, the patient’s risk profile, and their symptom burden. For low-risk PV, the cornerstone is phlebotomy (removing blood to keep the red blood cell count down) combined with low-dose aspirin. For low-risk ET, aspirin alone may suffice. When the risk of clotting is higher, or symptoms become troublesome, doctors add medications to lower cell counts. Hydroxyurea has been a workhorse drug for decades. Interferon-alpha is gaining ground as a disease-modifying option: rather than just controlling blood counts, it appears to push MPN stem cells into exhaustion, gradually reducing the mutant cell population over time.²⁴ Mathematical modeling suggests interferon is especially effective at depleting stem cells that carry two copies of the JAK2 mutation rather than one, which may explain why some patients see deep and lasting reductions in their mutant allele burden.

For myelofibrosis, the landscape shifted with the approval of ruxolitinib, a JAK1/JAK2 inhibitor. In randomized trials, ruxolitinib shrank enlarged spleens dramatically: about 28% of patients achieved at least a 35% reduction in spleen volume at 48 weeks, compared with none in the control group, and spleen size decreased on average by more than half.²⁵ Patients also reported significant improvements in quality of life and symptom relief, with responses proving durable over follow-up.²⁶ Since then, newer JAK inhibitors such as fedratinib, pacritinib, and momelotinib have been approved, each offering advantages for specific patient profiles. Pacritinib and momelotinib, for example, appear to carry a lower risk of worsening anemia, which matters a great deal for myelofibrosis patients who already have low blood counts.²⁷ However, none of the current JAK inhibitors have shown a clear overall survival benefit compared to ruxolitinib; their value lies in filling gaps for patients who can’t tolerate ruxolitinib or whose disease doesn’t respond to it.

The only treatment that can actually cure myelofibrosis is an allogeneic stem cell transplant, where a donor’s healthy blood-forming cells replace the patient’s diseased marrow. This is a high-stakes procedure. Among transplanted myelofibrosis patients who survive the first two years disease-free, ten-year disease-free survival was about 64% and overall survival about 74%, with better outcomes in younger patients and women.²⁸ The main cause of late death was relapse of the original disease. Improvements in donor matching, conditioning regimens, and supportive care continue to push results in the right direction, but transplant remains reserved for higher-risk patients because of the up-front dangers of graft failure, infection, and graft-versus-host disease.²⁹

MPNs and Pregnancy

Because essential thrombocythemia and polycythemia vera can be diagnosed in younger adults, pregnancy management comes up more often than you might expect for a blood cancer. Compared with the general population, women with MPNs have a lower live birth rate, about 71% versus 80%, along with higher rates of preterm birth and low birth weight.³⁰ First-trimester miscarriage is the most frequent complication, affecting roughly a third of pregnancies in ET and about a fifth in PV in older case series.³¹

Active management makes a real difference. In polycythemia vera, tight control of the hematocrit through blood removal, combined with low-dose aspirin and blood-thinning injections when needed, has been shown to dramatically improve outcomes. One small but striking series found that pregnancies managed without a formal protocol had poor results, while pregnancies managed with aggressive hematocrit control and aspirin had a live birth rate of over 90%.³² Interferon-alpha is considered the safest cytoreductive drug during pregnancy for women who need cell-count-lowering medication, as hydroxyurea and newer JAK inhibitors are generally avoided due to potential fetal harm.

Familial and Pediatric MPNs

Most MPNs occur sporadically, meaning no one else in the family has one. But familial clustering has been recognized for decades, and the genetic basis is becoming clearer. The strongest known predisposition factor for sporadic JAK2-mutated MPN is a common inherited variant called the JAK2 46/1 haplotype, which doesn’t cause the disease by itself but increases the odds that a JAK2 V617F mutation will develop over a lifetime.³³ Newer studies are expanding the list of susceptibility genes: inherited variants in TERT, MECOM, SH2B3, RBBP6, and ATM have all been linked to increased MPN risk, and very rare variants like chromosome 14q duplication cause hereditary MPN with high penetrance.³⁴

MPNs in children are extremely rare and appear to have a different genetic profile from adult cases. In a small series of pediatric patients, only about half carried any clinically significant genetic variant, and driver mutations like JAK2 V617F were less common than in adults. One child with primary myelofibrosis carried mutations in ten separate genes, a pattern more suggestive of complex clonal disease, and died of septic shock within months of diagnosis.³⁵ These cases remain poorly understood, and the pediatric MPN field has far less data to guide treatment decisions than the adult field does.

The Role of Non-Driver Mutations in Shaping Prognosis

When people hear “MPN genetics,” they tend to think of JAK2, CALR, and MPL. But the mutations that accumulate alongside these drivers can matter just as much for predicting how the disease will behave. Mutations in genes involved in epigenetic regulation (like ASXL1, TET2, and DNMT3A) and in RNA splicing (like SRSF2 and U2AF1) are being studied as markers of clonal evolution. Interestingly, common age-related blood mutations in TET2, ASXL1, and DNMT3A found at MPN diagnosis were not themselves significantly linked to blast transformation, but the presence of SRSF2 or U2AF1 mutations was a strong warning sign.³⁶ In primary myelofibrosis specifically, epigenetic mutations were strongly associated with a higher total number of mutations and tended to co-occur with spliceosome mutations, pointing to a more advanced and aggressive clone.³⁷ This is why next-generation sequencing panels are becoming standard at MPN diagnosis: identifying these companion mutations helps hematologists estimate how fast the disease may evolve and whether early, more aggressive treatment is warranted.